0000899243-22-014120.txt : 20220406 0000899243-22-014120.hdr.sgml : 20220406 20220406170238 ACCESSION NUMBER: 0000899243-22-014120 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220404 FILED AS OF DATE: 20220406 DATE AS OF CHANGE: 20220406 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanna Bastiano CENTRAL INDEX KEY: 0001829069 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 22811213 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-04 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001829069 Sanna Bastiano C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Cell & Genetic Therapies Common Stock 2022-04-04 4 S 0 305 267.10 D 46763 D Common Stock 2022-04-04 4 S 0 257 268.43 D 46506 D Common Stock 2022-04-05 4 S 0 3163 275.23 D 43343 D Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $267.10 (range $266.66 to $267.57). Open market sales reported on this line occurred at a weighted average price of $268.43 (range $267.81 to $268.78). Open market sales reported on this line occurred at a weighted average price of $275.23 (range $275.00 to $275.66). /s/ Sabrina Yohai, Attorney-in-Fact 2022-04-06